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Introduction: In health economic evaluations, mapping can be used to estimate utility values 
from other health outcomes in order to calculate quality adjusted life-years. Currently, no 
methods exist to map visual analog scale (VAS) scores to utility values. This study aimed to 
develop and propose a statistical algorithm for mapping five dimensions of health, measured 
on VASs, to utility scores in patients suffering from cardiovascular disease.
Methods: Patients undergoing coronary artery bypass grafting at Aalborg University Hospital 
in Denmark were asked to score their health using the five VAS items (mobility, self-care, 
 ability to perform usual activities, pain, and presence of anxiety or depression) and the EuroQol 
5 Dimensions questionnaire. Regression analysis was used to estimate four mapping models 
from patients’ age, sex, and the self-reported VAS scores. Prediction errors were compared 
between mapping models and on subsets of the observed utility scores. Agreement between 
predicted and observed values was assessed using Bland–Altman plots.
Results: Random effects generalized least squares (GLS) regression yielded the best results 
when quadratic terms of VAS scores were included. Mapping models fitted using the Tobit model 
and censored least absolute deviation regression did not appear superior to GLS  regression. The 
mapping models were able to explain approximately 63%–65% of the variation in the observed 
utility scores. The mean absolute error of predictions increased as the observed utility values 
decreased.
Conclusion: We concluded that it was possible to predict utility scores from VAS scores of the 
five dimensions of health used in the EuroQol questionnaires. However, the use of the mapping 
model may be inappropriate in more severe conditions.
Keywords: coronary artery bypass grafts, mapping, cross-walk, quality of life, outcomes 
research
Introduction
In health economic evaluations, the recommended measure of health effects is qual-
ity adjusted life-years, which enables the comparison of interventions across disease 
areas.1,2 However, clinical trials are frequently initiated without including questionnaires 
measuring preference-based health-related quality of life. Instead, nonpreference-based 
measures of health are often utilized and this renders it difficult to estimate health state 
utility values. One solution that is gaining popularity is prediction of utility values 
from the nonpreference-based measures of health. This is frequently called mapping 
and the technique requires an algorithm based on the statistical association between 
the tools.3 Mapping techniques have been applied in more than a quarter of technology 
appraisals submitted to the National Institute of Clinical Excellence.4 Most mapping 





techniques predict the utility values from disease-specific 
questionnaires.3 However, sometimes health effects are 
merely measured using a visual analog scale (VAS) instead of 
disease-specific  questionnaires. The VAS is one of the most 
frequently used methods for assessing pain intensity,5,6 and 
has also been applied in the assessment of depression,  anxiety, 
and mobility.7,8 Currently no method has been  developed for 
predicting utility scores from such VAS scores.
This study aimed to develop a mapping model to predict 
a single utility score from five VAS scores rating patients’ 
mobility, self-care, ability to perform usual activities, pain, 
and anxiety and depression. Such a model may be applied to 
map the partial effect of reducing patients’ pain measured on 
a VAS to utility scores, under the ceteris paribus assumption, 
ie, holding all other factors fixed.
We chose to estimate our mapping model by administer-
ing our questionnaire to patients undergoing coronary artery 
bypass grafting (CABG), for two reasons: 1) clinical trials 
investigating surgical interventions frequently use the VAS 
when assessing outcomes; and 2) patients undergoing CABG 
vary widely in the severity of their health conditions pre- and 




Data were prospectively collected between August 25, 2011 
and May 25, 2013, from patients recruited from the cardiotho-
racic surgical ward at Aalborg University Hospital, Denmark. 
Eligible patients were more than 18 years of age, were able 
to read Danish, and had coronary artery disease requiring 
elective CABG. Approximately 250 CABG procedures are 
performed at Aalborg University Hospital every year. We 
divided the dataset in two, by random sampling, such that 
60% of the patients were included in the estimation sample 
and the remaining 40% of the patients were included in the 
validation sample.
Questionnaires
For the purpose of developing the mapping-model, all patients 
were asked to complete the three level version of the EuroQol 
5 Dimensions questionnaire (EQ-5D) and to rate their per-
ceived health today on five VAS items (patients’ self-reported 
mobility, self-care, ability to perform usual activities, pain, 
and presence of anxiety or depression). Each VAS item was 
given an introductory title and a short statement representing 
“no problems” at 0 mm and a short statement representing 
“worst imaginable problems” at 100 mm.
Patients were asked to fill out the EQ-5D as many as three 
times. The first time was prior to their admission, the second 
time was 5 days postsurgery, and the third time was upon the 
arrival for their follow-up visit at the outpatient clinic. Only 
patients seen at the outpatient clinic at Aalborg University 
Hospital were asked to fill out the third questionnaire. In the 
analyses, each questionnaire was treated as an independent 
measurement in order to obtain diversity in the severity of 
health states.
analyses
For all mapping models, the dependent variable was the utility 
score calculated using the Danish time trade-off values.9 These 
values for the EQ-5D range from 1 to -0.624 where 1 indicates 
perfect health, 0 indicates death, and a value below zero is a 
health state perceived to be worse than death. We fitted two 
mapping-models using the 60% estimation sample. The first 
mapping model was fitted using age, sex, and the five VAS 
scores as explanatory variables. In the second mapping model, 
the squared terms of the five VAS scores were included. The 
squared terms were added in the second mapping model 
because the relationship between explanatory dimensions 
and utility scores may not be linear in nature.10,11 Although 
dimensions may not be additive,11,12 interaction terms were 
not considered as they may restrict the use of the mapping 
models to situations where all five VAS scores are measured. 
Excluding the interaction terms allows the mapping-models 
to be used in situations where only one or two of the VAS 
scores are measured. Both mapping models were initially fit-
ted using random intercepts generalized least squares (GLS) 
models. Least squared estimation was chosen because of its 
straightforward interpretation and frequent use in mapping 
models.3 The random effects part was chosen to handle the 
fact that some patients had multiple observations. However, 
if least squared estimation is used in the presence of large 
proportions of subjects scoring utility values of 1, the bounded 
nature of the utility value may result in implausible predictions 
outside of the existing range of the scale.3,13 In such situations, 
researchers have proposed using the Tobit model or censored 
least absolute deviation (CLAD) regression methods.3,14 If 
the proportion of patients at the upper ceiling is small the 
marginal coefficients from the random effects GLS should 
suffice.15 Nevertheless, to accommodate the possibility that the 
observed ceiling effect might reduce the performance of our 
random effects GLS models, random effects Tobit regression 
and CLAD regressions were also  fitted. The random effects 
Tobit regression handles the bounded nature of the utility 
scores and may therefore be an  appropriate alternative to least 




Mapping utility scores from visual analog scale scores
squares estimation.11,14,16 However, a random effects Tobit 
model will produce biased results when faced with heterosce-
dasticity or nonnormality.11,16 CLAD regression will produce 
consistent results even if faced with heteroscedasticity or 
 nonnormality.17 As such, the CLAD regression may seem the 
optimal choice. However, the downside to a CLAD mapping 
model is that it is a median model.13  Typically, economic 
evaluations use health valuations based on mean models. To 
assess the performance of the mapping models, we calculated 
the root mean squared error (RMSE) and mean absolute error 
(MAE) to compare the models.3,13 Errors were subsequently 
reported for the following subsets of observed utility values: 
utility ,0; 0# utility ,0.25; 0.25# utility ,0.5; 0.5# 
utility ,0.75; 0.75# utility #1.
We predicted the utility values in the validation sample 
using the second (full) random effects GLS mapping model 
to assess if the estimates were reliable. For both the esti-
mation sample and the validation sample, Bland–Altman 
plots were used to assess agreement between observed and 
predicted values. All statistical analyses were performed in 
Stata version 12.1 (StataCorp LP, College Station, TX, USA). 
The CLAD regression was performed using user-written 
programs for Stata.18 The questionnaires were entered once 
in EpiData version 3.1 (freeware product by EpiData Asso-
ciation, Odense, Denmark).
Results
A total of 238 patients were invited to enter the study. Of 
these, 24 patients declined the invitation, 16 did not meet 
inclusion criteria, and an additional 8 were excluded due 
to non-response (Figure 1). Therefore, 382 questionnaires 
from 190 patients were analyzed in the study. Because only 
patients seen at the outpatient clinic at Aalborg University 
Hospital filled out the third questionnaire, only 55 patients 
answered all three questionnaires. The baseline and intraop-
erative characteristics of the patients are shown in Table 1. No 
differences in patient characteristics were observed between 
the estimation dataset and validation dataset.
Figure 2 shows the five VAS items and the phrases used at 
both ends of the scale. The mean utility and VAS scores are 
reported in Table 2. The number of patients rating themselves 
in full health was somewhat limited, with observed utility 
scores ranging from -0.495 to 1 (Figure 3).
The first mapping model included age, sex, and the five 
VAS scores measuring health (GLS 1 in Table 3). Although 
the functional form of the explanatory variables was restricted 
to the additive level, the model explained approximately 63% 
of the variation in the EQ-5D utility score. In the second 
random effects GLS mapping model (GLS 2), the quadratic 
terms of the five VAS scores measuring health were added. 
Comparing the MAE and the RMSE between the two random 
effects GLS models, we found that the GLS 2 mapping model 
yielded the best fit to the estimation sample. Approximately 
65% of the variation in EQ-5D utility scores was explained 
by the GLS 2 mapping model. The variables used in the GLS 
2 model were also used to fit mapping models using random 
effects Tobit and CLAD regressions. The random effects 
Tobit mapping model was inferior to the GLS 2 mapping 
model, as it yielded higher MAE and RMSE values. The 
CLAD mapping model had a slightly lower MAE and a 
higher RMSE than the GLS 2 mapping-model had. In general, 
the mapping models performed better at higher observed 
EQ-5D utility scores (Table 4). In Figure 4 it can be seen that 
the reduction in performance in more severe health states is 
due to an over prediction of the EQ-5D utility score.
Bland–Altman plots of agreement between observed 
and predicted values of EQ-5D utility scores for the GLS 
2 model are shown in Figure 5. Figure 5A shows agreement 
in the estimation sample and Figure 5B shows agreement in 
the validation sample. In both samples, the mapping-model 
Table 1 Patients’ baseline and intraoperative characteristics







age (years), mean ± sD 68.4±9.2 65.9±9.6 0.07
Female, n (%) 25 (21.9) 13 (17.1) 0.42
Redo cardiac surgery, n (%) 2 (1.8) 0 (0) 0.52
Concomitant surgery, n (%) 20 (17.5) 18 (23.7) 0.30





Patients not fullfilling inclusion criteria
n=16
CABG not performed n=11
 Priority surgery n=4







Not analyzed due to non-response
n=8
(61 observations)
 Missing EQ-5D items (32 observations)
 Missing VAS items (29 observations)  
Randomly assigned to estimation group
n=114
(233 observations)  
Randomly assigned to validation group
n=76
(149 observations)  
Figure 1 Flowchart describing the inclusion of patients.
Abbreviations: n, number; CaBg, coronary artery bypass grafting; EQ-5D, 
EuroQol 5 Dimensions questionnaire; Vas, visual analog scale.





Table 2 Mean utility and Vas scores for all observations









EQ-5D utility score,  
mean ± sD
0.72±0.20 0.73±0.16 0.39
Vas mobility (mm),  
mean ± sD
26.8±22.4 26.6±20.3 0.91
Vas self-care (mm),  
mean ± sD
15.5±21.9 15.2±21.5 0.89
Vas usual activity (mm),  
mean ± sD
44.4±32.7 41.8±29.9 0.43
Vas pain (mm),  
mean ± sD
22.8±20.6 23.8±22.1 0.65
Vas anxiety and  




 Preoperative, n (%)
  Postoperative day 5,  
n (%)









Abbreviations: EQ-5D, EuroQol 5 Dimensions questionnaire; sD, standard 
deviation; Vas, visual analog scale; n, number.
My usual activities (eg, work, study, housework, family, or
leisure activities are):
Easy to manage










My pain can be described as:
No pain Unbearable
pain





Figure 2 Questionnaire used to assess health on visual analog scales.
0












Figure 3 Observed EQ-5D utility scores in the complete dataset.
Abbreviaton: EQ-5D, EuroQol 5 Dimensions questionnaire.



























































































































MaE 0.0857 0.0838 0.0871 0.0818
RMsE 0.121 0.119 0.120 0.141
Notes: *P,0.05; †P,0.01; ‡P,0.001.
Abbreviations: gls, generalized least squares; ClaD, censored least absolute 
deviation; sE, standard error; Vas, visual analog scale; MaE, mean absolute error; 
RMsE, root mean squared error.
overestimated the EQ-5D utility scores for patients with low 
observed EQ-5D utility scores. The Bland–Altman 95% 
limits of agreement from the validation sample (-0.212, 
0.240) were similar to those from the estimation sample 
(-0.233, 0.232). A slight bias of 0.014 was observed in the 
validation sample.
Discussion
The GLS 2 mapping-model showed promising ability to 
predict mean utility scores. Our findings indicate that VAS 
scores for mobility, self-care, usual activity, pain, and mood 
could be used for obtaining estimates of utility among 
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effect of reducing patients’ pain, under the ceteris paribus 
assumption, ie, holding all other factors fixed:



















Utility gain = (-0.00120*30 - 0.0000069*302)  
- (-0.00120*40 - 0.0000069*402)
Utility gain =(-0.0422) - (-0.0590) = 0.0168
In this example, it was estimated that a 10 mm reduction 
in pain measured on a VAS, from an average of 40 mm to 
an average of 30 mm, would increase patients’ utility with 
0.0168. Because the GLS 2 mapping-model contains squared 
terms, the utility gain from a 10 mm reduction on a VAS of 
pain depends on the severity of the pain, ie, the utility gain 
from a reduction in pain from 40 mm to 30 mm is not the 
same as from 60 mm to 50 mm. If the GLS 1 mapping model 
had been used, a 10 mm reduction on a VAS of pain would 
yield the same utility-gain regardless of the initial level of 
pain. The uncertainty in the estimated utility gain could be 
modeled using the standard errors of the coefficients from the 
mapping model in a probabilistic sensitivity analysis.
Strengths and limitations
Because we treated all measurements as independent obser-
vations, the observed utility scores covered a wide range, 
especially because patients temporarily felt worse 5 days 
after CABG. Naturally, this approach increases the sample 
size somewhat artificially, and the standard errors presented 
in Table 3 should therefore only be used to estimate approxi-
mate confidence intervals. However, by using each measure-
ment as independent we ensured that the mapping model 
is valid for all stages of the illness. The wide range of VAS 
scores and utility scores also enabled us to assess the GLS 
2 mapping model’s predictive ability at a subset of observed 
utility scores. This analysis showed that the reliability of 
our predictions declined as observed values decreased. This 
is a frequent limitation of mapping-models;3,11,19 however, 
it implies that the mapping models presented in this study 
may have a limited ability to predict utility scores for more 
severe conditions. Users of the mapping model should 
therefore be cautious when applying it in populations with 
large numbers of patients in poorer health. In such situa-
tions, alternative methods should be considered. The poor 
performance of the mapping model in patients with a more 
severe health condition is likely caused by a combination 
Table 4 Mean absolute error of mapping-models at subsets of 
observed EQ-5D utility scores


























Abbreviations: EQ-5D, EuroQol 5 Dimensions questionnaire; gls, generalized 













Figure 4 Mean observed and predicted EQ-5D utility scores in the validation 
sample.
Notes: The graph shows the agreement between the observed EQ-5D utility score 
and the mean of the predicted score. The observed health states are ordered on the 
x-axis according to their severity as valued by the Danish time trade-off tool.
Abbreviation: EQ-5D, EuroQol 5 Dimensions questionnaire.
patients with cardiovascular disease. As much as 65% of the 
variability in utility scores could be explained, which is quite 
high compared with existing mapping models.3 Goldsmith 
et al predicted EQ-5D utility scores in a group of patients 
with coronary artery disease using demographic and clinical 
outcome variables and explained 48%–49% of the variability 
in utility scores and found RMSE and MAE to be 0.170 and 
0.122, respectively.19 Longworth et al developed a model to 
map EQ-5D utility scores from clinical indicators for patients 
with stable angina and were able to explain 37% of the 
variation and showed an RMSE of 0.4764 (RMSE = √Mean 
Squared Error =√0.227).20 Our mapping-model may therefore 
be viewed as a reasonable method for mapping VAS scores 
to EQ-5D utility scores.
To illustrate the use of the GLS 2 mapping-model, imag-
ine a comparison of a new, less-invasive surgical method with 
the conventional open surgical method in a health economic 
evaluation. The new surgical method reduced pain measured 
on a VAS scale by 10 mm, from 40 mm to 30 mm. For sim-
plicity, assume that all other health outcomes are unchanged. 
The GLS 2 mapping-model is then applied to map the partial 






































Figure 5 Bland–altman plots of agreement between observed and predicted EQ-5D utility scores.
Notes: (A) agreement in the estimation sample. (B) agreement in the validation sample. The x-axis depicts the mean of the observed value and the predicted value, and 
the y-axis shows the difference (observed minus predicted). The lines show the mean difference, ie, the estimated bias, and the 95% limits of agreement (±1.96 sD of the 
mean difference).
Abbreviations: EQ-5D, EuroQol 5 Dimensions questionnaire; sD, standard deviation.
of the following: 1) the low number of patients with a low 
EQ-5D utility score in our dataset; 2) our exclusion of 
interaction terms and other covariates to ensure the map-
ping model could be used if researchers only had one of the 
five VAS measures; or 3) a larger intersubject variation in 
the use of the VAS scales for more severe conditions. The 
latter is supported by the fact that severe pain measured on 
a 11-point numeric rating scale could be from seven and 
upwards for some patients, while severe pain measured on 
a 100 mm VAS could be from 35 mm and upwards for oth-
ers.6 In another study, the over-prediction of EQ-5D utility 
scores was shown to be worsened by the N3-term, which 
is added if severe problems were reported in at least one 
dimension.11 However, the Danish time trade-off values for 
EQ-5D do not contain such a jump and therefore the N3 
term cannot be contributing to the over prediction among 
the severely ill in our analyses.9
The mapping models presented in this study were fit-
ted using patients undergoing cardiac surgery. Cost-effec-
tiveness analyses within this disease area have previously 
mapped health outcomes measured on VAS scales to utility 
scores.21,22 However, such attempts have also been made in 
other disease areas.23 Therefore, future work might include 
validating the mapping model for different patient groups 
and assessing the performance of an independent sample.
Conclusion
We conclude that it is possible to predict utility scores from 
VAS scores of the five dimensions of health used in the 
EuroQol questionnaires. However, the predictive power 
decreased as observed utility scores declined. The use of 
the mapping model may therefore be inappropriate in more 
severe conditions.
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